D. E. Shaw & Co., Inc. Cara Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 141,150 shares of CARA stock, worth $46,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares

141,150

Previous 146,854 3.88%

Holding current value

$46,579

Previous $108,000 18.52%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.52 - $1.05 $2,966 - $5,989	-5,704 Reduced 3.88%	141,150 $128,000
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.65 $88,112 - $242,309	146,854 New	146,854 $108,000
Q4 2022 Feb 14, 2023	SELL	$8.88 - $12.77 $196,576 - $282,689	-22,137 Reduced 48.89%	23,140 $248,000
Q3 2022 Nov 14, 2022	BUY	$8.24 - $12.56 $194,777 - $296,893	23,638 Added 109.24%	45,277 $424,000
Q2 2022 Aug 15, 2022	SELL	$7.45 - $13.84 $255,460 - $474,573	-34,290 Reduced 61.31%	21,639 $198,000

Q1 2022 May 16, 2022	BUY	$9.94 - $12.65 $555,934 - $707,501	55,929 New	55,929 $680,000
Q4 2021 Feb 14, 2022	SELL	$11.99 - $18.14 $264,835 - $400,676	-22,088 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.55 - $16.06 $1.02 Million - $1.42 Million	-88,158 Reduced 79.96%	22,088 $341,000
Q2 2021 Aug 16, 2021	SELL	$12.38 - $29.19 $1.53 Million - $3.61 Million	-123,763 Reduced 52.89%	110,246 $1.57 Million
Q1 2021 May 17, 2021	BUY	$15.07 - $21.71 $1.03 Million - $1.49 Million	68,601 Added 41.47%	234,009 $5.08 Million
Q4 2020 Feb 16, 2021	SELL	$12.72 - $16.16 $217,880 - $276,804	-17,129 Reduced 9.38%	165,408 $2.5 Million
Q3 2020 Nov 16, 2020	SELL	$12.34 - $17.92 $2.37 Million - $3.44 Million	-192,152 Reduced 51.28%	182,537 $2.32 Million
Q2 2020 Aug 14, 2020	SELL	$12.39 - $17.33 $1.52 Million - $2.13 Million	-122,993 Reduced 24.71%	374,689 $6.41 Million
Q1 2020 May 15, 2020	BUY	$9.12 - $17.78 $2.25 Million - $4.39 Million	246,736 Added 98.32%	497,682 $6.57 Million
Q4 2019 Feb 14, 2020	BUY	$16.11 - $25.98 $1.94 Million - $3.12 Million	120,246 Added 92.0%	250,946 $4.04 Million
Q3 2019 Nov 14, 2019	BUY	$18.28 - $26.91 $1.59 Million - $2.34 Million	87,077 Added 199.61%	130,700 $2.39 Million
Q2 2019 Aug 14, 2019	BUY	$17.68 - $21.57 $771,254 - $940,948	43,623 New	43,623 $938,000
Q4 2018 Feb 14, 2019	SELL	$12.45 - $23.47 $564,557 - $1.06 Million	-45,346 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$17.57 - $23.95 $796,729 - $1.09 Million	45,346 New	45,346 $1.09 Million
Q1 2018 May 15, 2018	SELL	$11.77 - $16.08 $121,760 - $166,347	-10,345 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$11.86 - $14.08 $26,068 - $30,947	-2,198 Reduced 17.52%	10,345 $127,000
Q3 2017 Nov 14, 2017	BUY	$12.6 - $16.34 $158,041 - $204,952	12,543	12,543 $172,000

Others Institutions Holding CARA

# of Institutions

102

Shares Held

21.5M

Call Options Held

50K

Put Options Held

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $17.7M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account